FDA/Panel Decisions
FONT-SIZE Plus   Neg
Share SHARE

FDA Approves Eli Lilly's New Alzheimer's Screening Test

FDA Approves Eli Lilly's New Alzheimer's Screening Test

The FDA has given its approval to Ely Lilly and Company's new Alzheimer's testing procedure called Amyvid. The test uses a radioactive ink that allows doctors to screen for a plaque in the brain that has been tied to Alzheimer's.

According to foxnews.com, when injected into the bloodstream the radioactive ink binds the to harmful plaque beta amyloid, which is then illuminated on a positron emission topography scan.

Lilly will sell the product through its Avid Radiopharmaceuticals Inc. brand and the brand's CEO Dr. Daniel Skovronsky says it will add a new tool for doctors to use in diagnosing the ailment:

"The approval of Amyvid offers physicians a tool that, in conjunction with other diagnostic evaluations, can provide information to help physicians evaluate their patients," he said in the company's statement from Friday.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.